Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of daptomycin for Staphylococcus aureus spondylodiscitis
2009-017704-86Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Apr 2010
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daptomycin in discitis, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Efficacy of treatment after 3 months from the starting of therapy. Started Apr 2010; status: terminated.
02
Drugs
daptomycin
03
Conditions
discitis
Beyond the preview
Go deeper on 2009-017704-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017704-86.